Home » Newsletters » BioWorld Science

BioWorld Science

March 21, 2000

View Archived Issues

Progenics expands HIV program with Pharmacopeia, receives SBIR grant

Phase I trial results presented for IDEC-114 antibody in psoriasis

Sanofi-Synthelabo presents overhauled R&D portfolio to financial analysts

New introduction for consensus interferon in major European market

BMS withdraws NDA for UFT and Orzel, plans to resubmit

Clinical testing of solid oral dosage form of heparin commences

Zambon and Sheffield submit IND to FDA for MSI-ipratropium bromide

Bayer licenses anticancer compound from Indena

AVI BioPharma successfully completes phase I trials of Resten-NG

ADIR prepares potent and selective 5-HT1B receptor ligands

New integrin alphav receptor antagonists patented by Merck

Lilly discloses new indole sPLA2 inhibitors

Antimicrobial mutilin derivatives for Gram-positive, Gram-negative and mycoplasmal infections

Aminomethylcarboxylic acid derivatives as inhibitors of glycine transport

Novel anticonvulsants continue as area of focus at SB

Novel class of human 5alpha-reductase inhibitors undergoes evaluation at Yamanouchi

Zyprexa approved in U.S. for bipolar-associated mania

LY-293558, a new glutamate receptor antagonist, evaluated for safety and analgesic efficacy

FDA's ODAC recommends approval of Mylotarg for relapsed AML

European authorities request comparison studies of dexmedetomidine in ICU

ASCPT news: pharmacodynamics of VPA-985 + hydrochlorothiazide in humans

Medinox's NO neutralizer prevents transplant rejection in preclinical study

Health Canada approves AmBisome as antifungal treatment

Tarazepide demonstrates activity as CCK-A antagonist in early clinical trials

Orion licenses deramciclane from Egis and begins phase III program in anxiety

Korean K+ channel activator SKP-450 has promising PK/PD profile in healthy subjects

Phase I results for CVT-510 presented at ACR meeting; CV designs new partial agonist derivative

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Feb. 6, 2025.
MJFF grant supports Bexorg’s translational biomarker work
BioWorld Science
Bexorg Inc. has been awarded a research grant from The Michael J. Fox Foundation for Parkinson’s Research (MJFF) through the Targets to Therapies initiative to...
REST emerges as biomarker in ALS, knockdown improves ALS symptoms
BioWorld Science
About 10% of amyotrophic lateral sclerosis (ALS) cases result from inherited genetic mutations, with about 20% of them attributed to mutations in the gene...
Serotonin receptor modulators for the treatment of OUD
BioWorld Science
Opioid use disorder (OUD) causes high morbidity and mortality rates, with fentanyl driving unprecedented overdose rates. Researchers from the University of...
KLF15 shows potential as marker, target for cholangiocarcinoma
BioWorld Science
Researchers at the Biodonostia Health Research Institute reported on the role of KLF15 in cholangiocarcinogenesis and its potential as a therapeutic target in...